2015

Serodus has been invited to attend the 34^th Annual J.P. Morgan Healthcare Conference January 11-14, 2016. 

Oslo, Norway, 17 December 2015: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the formation of a new Scientific Advisory Board for the development program in Acute Myocardial Infarction (SER130).

Oslo, 16 December, 2015: Serodus ASA (Oslo Axess: SER) presented the company and its drug candidates at the DNB Healthcare conference in Oslo. The presentation is available on www.serodus.com in the section for Investor/Presentations and publications.

Oslo, December 10, 2015: Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 125 000 shares at an average price of NOK 2,1495 per share. After registration of these shares Dr. Steiness has 1 805 954 shares and 100 000 warrants.

Oslo, Norway, 09 December 2015: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the formation of a new Scientific Advisory Board for the development program in Diabetic Nephropathy.

Oslo, 03 November, 2015: Serodus ASA (Oslo Axess: SER) will present the company and its drug candidates at the BIO Europe 2015 in Munich. The company presentation will highlight the diabetes projects.

Oslo, October 28, 2015: Serodus ASA (Oslo Axess: SER), a Scandinavian biotech company with focus on cardiovascular and metabolic diseases, has filed a new provisional patent for SER140. The peptide SER140 is an IL-1 receptor antagonist derived from the human IL-1 sequence.

Oslo, 27. October 2015. Serodus ASA (OAX:SER) announces its results for the third quarter 2015. 

Oslo – 21. October 2015 – Serodus ASA (Oslo Axess, SER) will present the Q3 results 2015 at Hotel Continental, Stortingsgaten 24/26, Oslo, Tuesday 27 October 2015 at 08:00. The presentation will be held by CEO Eva Steiness and CFO Tore Kvam.

Oslo, September 17, 2015: Reference is made to the completed Rights issue. The result of the from the subscription is as follow:

Reference is made to Serodus ASA's previous announcements regarding the result of its rights issue raising gross proceed of approximately NOK 25 million.

Reference is made to Serodus ASA's (the "Company") 
previous announcements regarding the rights issue of 
minimum 9,259,260 and maximum 11,111,111 new shares 
raising gross proceed of minimum NOK 25 million and 
maximum NOK 30 million (the "Rights Issue").

Reference is made to Serodus ASA's (the "Company") previous announcements regarding the rights issue. The subscription period for Rights Issue and trading in the subscription rights expired on 3 September 2015 at 16:30.

Reference is made to Serodus ASA's (the "Company") 

previous announcements regarding the rights issue of 
minimum 9,259,260 and maximum 11,111,111 new shares 
raising gross proceed of minimum NOK 25 million and 
maximum NOK 30 million (the "Rights Issue").

September 2015 at 16:30.The subscription period for Rights Issue expired on 3

Oslo, September 4, 2015: Reference is made to the ongoing Rights issue, the Chairman of the board Svein Jacobsen has requested a purchase of 100 000 shares in the Rights issue at an price of NOK 2,70 per share through his wholly owned company Sveinja Invest AS.  He holds 54 621 subscription rights in the Right issue.

Serodus has today appointed Nikolai C. Brun as Vice President Drug Development. Dr. Brun is an MD, PhD from the University of Copenhagen and has an extensive experience from the pharmaceutical industry with a strong track record from clinical development.

The extraordinary general meeting in Serodus ASA was held on 17 August 2015 ("EGM"). A copy of the minutes from the EGM is attached.

Oslo, 14. August 2015. Serodus ASA (OAX:SER) announces its results for the second quarter 2015. 

Serodus, today announced that the first patients are randomized in the SER150 multi-center, double-blind, randomized, placebo controlled Phase IIa clinical trial in patients suffering from Diabetic nephropathy. SER150 is a first-in-class anti-inflammatory compound, with a dual anti thrombotic mode of action.

Oslo – 11. August 2015 – Serodus ASA (Oslo Axess, SER) will present the Q2 results 2015 at Hotel Continental, Stortingsgaten 24/26, Oslo, Friday 14 August 2015 at 08:30. The presentation will be held by CEO Eva Steiness and CFO Tore Kvam.

Oslo, (24. July 2015) Reference is made to the notification July 8^th, 2015.  The extraordinary general meeting of Serodus ASA will be held on 17 August 2015 at 13:00 at Forskningsparken, Gaustadalleen 21, 0349 Oslo. Meeting room Hagen 5.

Oslo, 8. July 2015; Reference is made to Serodus ASA ("Serodus" or the "Company") quarterly report published on 24 April 2015 regarding the financing process. After evaluation of the Company’s financing requirements and alternatives, the Board of Directors (the "Board") of Serodus has resolved to propose an underwritten rights issue of minimum NOK 25 million and maximum NOK 30 million at a price of NOK 2.70 per share, with pre-emptive subscription rights for existing shareholders (the “Rights Issue”), to strengthen the Company's financial position. The Board will call for an extraordinary general meeting (the “EGM”) expected to be held on or about 17 August 2015 to resolve the Rights Issue.

Oslo, June 23, 2015: Serodus ASA (Oslo Axess: SER), a Norwegian biotech company, today announced that the Japanese Patent Office has granted to Serodus Patent No. 5750373 titled, “IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases”.

Oslo, 15 June, 2015: Serodus ASA (Oslo Axess: SER) received approval for a Clinical Trial Application from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a Phase IIa safety study with SER150 in patients diagnosed with diabetic nephropathy.

Oslo, 10 June 2015: Serodus ASA (Oslo Axess: SER) today announces that the company will present its drug candidates at the 2015 BIO International Convention in Philadelphia, USA on 15-17 June 2015.   

(21 May 2015) Serodus ASA (OSE:SER). The Ordinary General Assembly Meeting of Serodus ASA today adopted all the items as proposed on the agenda.

Oslo, 18 May, 2015: Serodus ASA (Oslo Axess: SER) today announced that Eva Steiness, CEO and Tore Kvam, CFO, will present the company and its drug candidates at the BIOEquity Conference in Vienna, Austria on 19 May, 2015 at 5.40 pm.

Oslo, (30.04.2015) The annual general meeting of Serodus ASA will be held on 21 May 2015 at 15:00 at Forskningsparken, Gaustadalleen 21, 0349 Oslo. Meetingroom Hagen 5.

Serodus today announced the appointment of Peter Holm Tygesen as Vice President Pharmaceutical Development. The company continues its actions moving forward to establish future partnerships.

Oslo, 24. April 2015. Serodus ASA (OAX:SER) announces its results for the first quarter 2015. A webcast and presentations are available her.

Oslo, April 20, 2015: Serodus ASA (Oslo Axess: SER) has filed a Provisional patent application for the Orphan Diseases of Pulmonary Hypertension to the United Kingdom patent office.

Oslo – 16. April 2015 – Serodus ASA (Oslo Axess, SER) invites to a presentation of the company's first quarterly report 2015 on Friday 24 April 2015.

Oslo – April 2015 – Serodus ASA (Oslo Axess, SER) a Norwegian biotechnology company focused on developing novel innovative treatment within cardiovascular and metabolic diseases, today announced that the European Medicines Agency (EMA) has granted Serodus SME (Small and Medium Sized Business Entities) status.

Oslo, April 14, 2015: Serodus ASA (Oslo Axess: SER), a Norwegian biotech company, today announced that Russia’s Federal Service for Intellectual Property has granted to Serodus Patent No. 2011121971 titled, “IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases”.

Oslo, April 09, 2015: Serodus ASA (Oslo Axess: SER) announces the strengthening of its management team with the employment of Jürgen Langhärig as Vice President, Business Development.

Oslo, February 26, 2015: Serodus ASA (Oslo Axess: SER) Tore Kvam (CFO) has today purchased 10 000 shares at an average price of NOK 2,80 per share through his wholly owned company Itza AS. After registration of these shares Tore Kvam owns 30 000 shares through his wholly owned company Itza AS.

Oslo, February 18, 2015: Serodus ASA (Oslo Axess: SER) has today filed a Clinical Trial Application with the German authorities for a Phase IIa study on SER150 diabetic nephropathy.

Oslo, February 12, 2015: Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 45 898 shares at an average price of NOK 2,708 per share. After registration of these shares Dr. Steiness has 931 939 shares and 100 000 warrants.

The fourth quarterly report 2014 is available attached. Highlights from the report are:

Oslo, January 12, 2014

Serodus ASA (Oslo Axess: SER) CEO, Eva Steiness will present Serodus to the 7th Annual Biotech Showcase conference in San Francisco Monday 12th of January 2015. The presentation will take place at 5PM at the Parc 55 Wyndham San Francisco Hotel. The slides from the presentation will be available in the Investor relations section of the company's website after the conference. Serodus will also have meetings with a spectrum of pharmaceutical companies with the purpose of having strategic discussions about the company's R&D portfolio.

Serodus ASA (Oslo Axess: SER) will present the company during the JP Morgan Annual Health Conference January 11-15, 2015.